About R5 Pharmaceuticals
R5 Pharmaceuticals is a Healthcare company based in Nottingham (United Kingdom) founded in 2006, and was acquired by Aesica in June 2010. It develops formulations for clinical trials ranging from solid-dose capsules to liquids and injectables. R5 Pharmaceuticals has raised $494.31 thousand across 3 funding rounds from investors including Aesica. Its focus areas include Biopharma Outsourcing, CDMO and Diversified.
Company details
R5 Pharmaceuticals was established in 2006 in Nottingham, United Kingdom, within the pharmaceutical sector. GMP facilities were operated to produce dosage forms such as tablets, capsules, creams, ointments, and injectables, supported by an analytical laboratory for method development, quality control, and stability testing. Services were provided for formulating and analyzing synthetic and biotech materials, including cytotoxic APIs, proteins, and peptides. The company was acquired by Aesica in July 2010.
- Headquarters Nottingham, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website r5pharma.com
- Acquired by Aesica (Jun 2010)
Funding Insights of R5 Pharmaceuticals
R5 Pharmaceuticals has successfully raised a total of $494.31K across 3 strategic funding rounds. The most recent funding activity was a Grant round of $28.85 thousand completed in November 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $494,305
- Total Rounds 3
- Last Round Grant — $28,850
- First Round $494,305
(Apr 2007)
All 3 funding rounds of R5 Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2011 | $28,850 | Grant | – | – | – |
| Jun 2011 | $320,562 | Grant | – | – | – |
| Apr 2007 | $494,305 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in R5 Pharmaceuticals
R5 Pharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include Aesica.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Contract development and manufacturing organisation (CDMO) for APIs and finished dose forms | 2004 | aesica-pharma.com | Newcastle Upon Tyne, United Kingdom |
Investor details for R5 Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of R5 Pharmaceuticals
4 dated milestones of R5 Pharmaceuticals across 5 years, from founding to its latest funding, stage changes and deals.
- Founded R5 Pharmaceuticals is founded.
- Funding First funding round of $494K.
- Exit Acquired by Aesica.
- Funding Latest funding round, Grant, of $29K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about R5 Pharmaceuticals
R5 Pharmaceuticals was founded in 2006 and raised its 1st funding round 1 year after it was founded.
R5 Pharmaceuticals is headquartered in Nottingham, United Kingdom.
R5 Pharmaceuticals is a funded company, having raised a total of $494.31K across 3 funding rounds to date. The company's 1st funding round was a Seed of $494.31K, raised on Apr 2007.
R5 Pharmaceuticals was established in 2006 in Nottingham, United Kingdom, within the pharmaceutical sector. GMP facilities were operated to produce dosage forms such as tablets, capsules, creams, ointments, and injectables, supported by an analytical laboratory for method development, quality control, and stability testing. Services were provided for formulating and analyzing synthetic and biotech materials, including cytotoxic APIs, proteins, and peptides. The company was acquired by Aesica in July 2010.
R5 Pharmaceuticals has 1 investor. Key investors include Aesica.
Yes. R5 Pharmaceuticals was acquired by Aesica in June 2010.